At a glance
ClinicalIndex Comparison RecordN/ACompleted· 140 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Spoken Language Biomarker of Cognitive Impairment in PD
In Brief
An observational study for Parkinson Disease. Completed, enrolled 140 participants across 1 site.
Detailed Summary
The purpose of this study is to identify unique profiles of speech and language changes that distinguish individuals with Parkinson's disease from adults without Parkinson's disease and individuals with Parkinson's disease with cognitive (e.g., memory, thinking skills) impairment from those without cognitive impairment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2019
Primary CompletionFeb 2023
First PostedJun 2023
TodayJul 2026
First PostedJun 18, 2023
Enrollment StartMar 5, 2019
Primary CompletionFeb 15, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 3.0 years ago